Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study

American Heart Journal

Volumn 158, Issue 4, 2009, Pages

  Zhao, Shui ping ^a   Peng, Dao quan ^a   Yu, Bi lian ^a   Huo, Yong ^b  

^a CHANGSHA UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SAFETY; HEART DEATH; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; METHODOLOGY; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 70349197614     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.07.030     Document Type: Article

References (15)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. MRC/BHF Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
3. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
4. Cannon C.P., Braunwald E., Mccabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
5. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1405-1410
6. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 113 (2006) 2363-2372
7. Wiviott S.D., de Lemos J.A., Cannon C.P., et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 113 (2006) 1406-1414
8. Ito H., Ouchi Y., Ohashi Y., et al. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: The pravastatin anti-atherosclerosis trial in the elderly (PATE). J Atheroscler Thromb 8 (2001) 33-44
9. West of Scotland Coronary Prevention Study Group. Effect of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97 (1998) 1440-1445
10. Sacks F.M., Moye L.A., Davis B.R., et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation 97 (1998) 1446-1452
11. Miyauchi K., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 70 (2006) 1624-1628
12. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
13. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1993), National Institutes of Health, Bethesda (Md)
14. Amarenco P., Bogousslavsky J., Callahan III A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
15. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435